GlassScriptPhysician profile
Michael J Greely
NPI 1164520615
$1,183.00
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $201.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.33 | 2019-2020 | |
| Amgen INC. | $199.87 | 2019-2020 | |
| Novo Nordisk INC | $115.82 | 2019-2020 | |
| Daiichi Sankyo INC. | $112.97 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $75.08 | 2019 | |
| Glaxosmithkline, LLC. | $63.10 | 2019-2020 | |
| Pfizer INC. | $60.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $46.00 | 2019 | |
| Astellas Pharma US INC | $37.38 | 2019 | |
| Horizon Therapeutics Plc | $36.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $20.94 | 2019 | |
| Bausch Health US, LLC | $17.96 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Greely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.